Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Predicting Neuropsychiatric Symptoms of Parkinson’s Disease with Measures of Striatal Dopaminergic Deficiency

Author(s): Ram Bishnoi*, Marina C. Badir, Sandarsh Surya and Nagy A. Youssef

Volume 18, Issue 6, 2021

Published on: 27 August, 2021

Page: [499 - 504] Pages: 6

DOI: 10.2174/1567205018666210827122133

Price: $65

Abstract

Background: The role of nigrostriatal dopaminergic neurons degeneration is well established in the pathophysiology of Parkinson’s disease. However, it is unclear if and how the degeneration of the dopamine pathways affects the manifestation of the neuropsychiatric symptoms (NPS) of Parkinson’s Disease (PD). Dopamine transporter (DAT) imaging, a technique to measure the reduction in dopamine transporters is increasingly used as a tool in the diagnosis of PD.

Methods: In this study, we examine if the baseline dopamine transporter density in the striatum measured by the Striatal Binding Ratio (SBR) is associated with the longitudinal onset and/or progression of NPS in PD as measured by part 1 of Movement Disorder Society - Unified Parkinson's Disease Rating Scale, over four years. Data of patients with PD and an abnormal screening present on 123I-ioflupane single-proton emission computed tomography were obtained from Parkinson's Progression Markers Initiative (PPMI) database. Latent Growth Modeling (LGM), a statistical technique that can model the change over time while considering the variability in the rate of change at the individual level, was used to examine the progression of NPS over time.

Results: The results indicate the SBR did not correlate with the baseline NPS but did correlate with the rate of change of NPS (p<0.001) over the next four years, even after eliminating age-related variance, which can be a significant confounding factor.

Conclusion: In conclusion, this study showed gradual worsening in NPS in patients with Parkinson’s disease, which inversely correlates with the density of the dopamine transporters as measured by SBR at baseline.

Keywords: Neuropsychiatric symptoms, Parkinson's disease, dopamine, striatum, neuroimaging, latent growth modeling.

« Previous Next »
[1]
Weintraub D, Mamikonyan E. The neuropsychiatry of Parkinson disease: A perfect storm. Am J Geriatr Psychiatry 2019; 27(9): 998-1018.
[http://dx.doi.org/10.1016/j.jagp.2019.03.002] [PMID: 31006550]
[2]
Weintraub D, Simuni T, Caspell-Garcia C, et al. Initiative PsPM. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord 2015; 30(7): 919-27.
[http://dx.doi.org/10.1002/mds.26170] [PMID: 25737166]
[3]
Aarsland D, Brønnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 2009; 80(8): 928-30.
[http://dx.doi.org/10.1136/jnnp.2008.166959] [PMID: 19608786]
[4]
Dujardin K, Sockeel P, Delliaux M, Destée A, Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 2009; 24(16): 2391-7.
[http://dx.doi.org/10.1002/mds.22843] [PMID: 19908317]
[5]
Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992; 55(5): 377-82.
[http://dx.doi.org/10.1136/jnnp.55.5.377] [PMID: 1602311]
[6]
Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson’s disease: role of aging. Ann Neurol 1989; 26(4): 551-7.
[http://dx.doi.org/10.1002/ana.410260409] [PMID: 2817829]
[7]
Isaacson SH, Fisher S, Gupta F, et al. Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Rev Neurother 2017; 17(3): 219-25.
[http://dx.doi.org/10.1080/14737175.2017.1256205] [PMID: 27813429]
[8]
Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis 2010; 39(1): 98-104.
[http://dx.doi.org/10.1016/j.nbd.2010.03.013] [PMID: 20338240]
[9]
Santangelo G, Vitale C, Picillo M, et al. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson’s disease patients. Parkinsonism Relat Disord 2015; 21(5): 489-93.
[http://dx.doi.org/10.1016/j.parkreldis.2015.02.015] [PMID: 25753457]
[10]
Roselli F, Pisciotta NM, Perneczky R, et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 2009; 24(14): 2097-103.
[http://dx.doi.org/10.1002/mds.22702] [PMID: 19705471]
[11]
Ye BS, Jeon S, Yoon S, et al. Effects of dopaminergic depletion and brain atrophy on neuropsychiatric symptoms in de novo Parkinson’s disease. J Neurol Neurosurg Psychiatry 2018; 89(2): 197-204.
[http://dx.doi.org/10.1136/jnnp-2017-316075] [PMID: 28951497]
[12]
Erro R, Pappatà S, Amboni M, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord 2012; 18(9): 1034-8.
[http://dx.doi.org/10.1016/j.parkreldis.2012.05.022] [PMID: 22789824]
[13]
Felicio AC, Moriyama TS, Godeiro-Junior C, et al. Higher dopamine transporter density in Parkinson’s disease patients with depression. Psychopharmacology (Berl) 2010; 211(1): 27-31.
[http://dx.doi.org/10.1007/s00213-010-1867-y] [PMID: 20495790]
[14]
Goetz CG, Tilley BC, Shaftman SR, et al. Force MDSURT. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23(15): 2129-70.
[http://dx.doi.org/10.1002/mds.22340] [PMID: 19025984]
[15]
Hess B. Assessing program impact using latent growth modeling: a primer for the evaluator. Eval Program Plann 2000; 23: 419-28.
[http://dx.doi.org/10.1016/S0149-7189(00)00032-X]
[16]
Choi Y, Golder S, Gillmore MR, Morrison DM. Analysis with missing data in social work research. J Soc Serv Res 2005; 31: 23-48.
[http://dx.doi.org/10.1300/J079v31n03_02]
[17]
Jöreskog KG, Sörbom D. LISREL 8: Structural equation modeling with the SIMPLIS command language. Scientific Software International 1993.
[18]
Hu L-t, Bentler PM. Fit indices in covariance structure modeling: Sensitivity to underparameterized model misspecification. Psychol Methods 1998; 3: 424.
[http://dx.doi.org/10.1037/1082-989X.3.4.424]
[19]
Cole JH, Marioni RE, Harris SE, Deary IJ. Brain age and other bodily ‘ages’: implications for neuropsychiatry. Mol Psychiatry 2019; 24(2): 266-81.
[http://dx.doi.org/10.1038/s41380-018-0098-1] [PMID: 29892055]
[20]
Vriend C, Raijmakers P, Veltman DJ, et al. Depressive symptoms in Parkinson’s disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry 2014; 85(2): 159-64.
[http://dx.doi.org/10.1136/jnnp-2012-304811] [PMID: 23813742]
[21]
Ravina B, Marek K, Eberly S, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson’s disease. Mov Disord 2012; 27(11): 1392-7.
[http://dx.doi.org/10.1002/mds.25157] [PMID: 22976926]
[22]
Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med 2005; 46(2): 227-32.
[PMID: 15695780]
[23]
Park SB, Kwon KY, Lee JY, et al. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson’s disease: a detailed PET analysis of 12 striatal subregions. Neurol Sci 2019; 40(2): 311-7.
[http://dx.doi.org/10.1007/s10072-018-3632-7] [PMID: 30415448]
[24]
Yousaf T, Pagano G, Niccolini F, Politis M. Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2). J Neurol 2019; 266(5): 1203-10.
[http://dx.doi.org/10.1007/s00415-019-09250-y] [PMID: 30820739]
[25]
Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167(7): 748-51.
[http://dx.doi.org/10.1176/appi.ajp.2010.09091379] [PMID: 20595427]
[26]
Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry 2014; 171(4): 395-7.
[http://dx.doi.org/10.1176/appi.ajp.2014.14020138] [PMID: 24687194]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy